-
Rapid Detection of COVID-19 & Influenza A/B Antigens
-
Provides Results in Approximately 15 Minutes
-
Uses Direct Anterior Nasal Swab Specimens
-
Features Instrument-Free Lateral Flow Technology
-
Supports Professional Point-of-Care Testing .
The Aqueous Diagnostics Nano-Check Influenza + COVID-19 Dual Rapid Test is a rapid lateral flow immunochromatographic assay intended for the qualitative detection and differentiation of SARS-CoV-2 nucleocapsid antigen, Influenza A nucleoprotein antigen, and Influenza B nucleoprotein antigen. Designed for professional in vitro diagnostic use, the test delivers visually interpreted results in just a few minutes, making it suitable for point-of-care testing environments.
✔ DUAL RESPIRATORY VIRUS DETECTION | ✔ 15-MINUTE RESULTS | ✔ RAPID POINT-OF-CARE TESTING
FAST & EFFICIENT RESPIRATORY VIRUS DETECTION
-
SIMULTANEOUS ANTIGEN DETECTION: Qualitatively detects and differentiates SARS-CoV-2 nucleocapsid antigen, Influenza A nucleoprotein antigen, and Influenza B nucleoprotein antigen from a single direct anterior nasal swab specimen.
-
RAPID VISUAL RESULTS: Produces visually interpreted results in approximately 15 minutes, supporting timely patient assessment in point-of-care settings.
-
PROFESSIONAL IN VITRO DIAGNOSTIC USE: Intended for use by trained healthcare professionals in appropriate clinical and point-of-care settings for patients presenting with signs and symptoms of respiratory tract infection.
-
INSTRUMENT-FREE OPERATION: Designed for visual interpretation without the need for laboratory analyzers or electronic readers, providing a simple workflow for rapid respiratory testing.
STREAMLINED POINT-OF-CARE WORKFLOW
-
DIRECT ANTERIOR NASAL COLLECTION: Utilizes direct anterior nasal swab specimens, providing a convenient and minimally invasive specimen collection method for respiratory virus testing.
-
COMPLETE TEST KIT: Sold as 25 tests per kit, including the components required to perform the test, such as test cassettes, buffer tubes, swabs, controls, and instruction guide.
-
POINT-OF-CARE READY: FDA 510(k)-cleared and CLIA-waived, supporting rapid respiratory virus testing in eligible professional healthcare settings.
-
COMPACT TEST FORMAT: The compact, instrument-free design supports efficient respiratory testing in clinics, physician offices, urgent care centers, and other professional healthcare environments
The Aqueous Diagnostics Nano-Check Influenza + COVID-19 Dual Rapid Test provides healthcare professionals with a convenient solution for the qualitative detection and differentiation of COVID-19, Influenza A, and Influenza B, combining rapid 15-minute results with a simple, instrument-free workflow to support timely clinical decision-making.
**FDA Disclaimer: This combination test is not FDA cleared or approved, but only authorized under an Emergency Use Authorization for use by authorized laboratories. It is authorized for the rapid detection of proteins from SARS-CoV-2, Influenza A and B, and not for any other viruses or pathogens. This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for the detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
WARNING: This product can expose you to chemicals known to the State of California to cause cancer. For more information, go to www.P65Warnings.ca.gov.
